å ç«äœäžãåãŸããªã瀟äŒ
仿ããå°å ã®ã¢ãããŠã€ã«ã¹ææçæ£è æ°ãçµ±èšéå§ä»¥æ¥æå€§ã«ããšããå ±éãèŠãŸããã
ãªããšããããå°ããªåã©ããã¡ã®å 圹ã®ç¶æ ãäžåã«è¯ããªã£ãŠããªããã ãªããšæ¹ããŠç¥ããŸãã
æ¯æ¥ã®ããã«éãéã«ããè¿æã®å°å ç§ã飿¥ãé§è»å Žãæºè»ãšãªã£ãŠããŠããã®å°å ç§ã¯å®å šäºçŽå¶ã«ãé¢ãããåžžã«æºè»ãšããã®ã¯ã倧å€ãªããšã«ãªã£ãŠããã®ã ãããªãšãæããŸãã
å®éã«ã¯ãããšãã°ã€ã³ãã«ãšã³ã¶ã«ããŠããã¢ãããŠã€ã«ã¹ã«ããŠããç é¢ã«è¡ã£ãŠæ²»ããæ¹æ³ãè¬ãããããã§ã¯ãªãã§ãããå®¶ã§éãã«å¯ãããŠããã®ãäžçªã ãšæãã®ã§ããã©ãâŠã
ä»å¹Žã® 6æã«ã¯ãã¢ã¡ãªã«å»åž«äŒéèªïŒJAMAïŒã«ãã«ã¿ããã«ãåŠæ¹ããŠãå ¥é¢ã¯æžããªãããšããè«æãåºãŠããããšããããŸããã
ïŒèšäºïŒã€ã³ãã«ãšã³ã¶æ£è
ã«ã¿ããã«ãåŠæ¹ããŠãå
¥é¢ã¯æžããªããšããææ°ã®ã¡ã¿ç ç©¶
ãBDW 2023幎6æ14æ¥
ããšã¯ãåŠæ¹ããããšããã°ãè§£ç±å€ã§ãããã
ããã¯ãã培åºçã«è¯ããªãã§ããã
ïŒèšäºïŒåã©ããã¿ããªè§£ç±å€ã§ããããŠããŸã
ãIn Deep 2022幎8æ27æ¥
ãã®èšäºã«ãããã¶ã以åã®ãã®ã§ãããæ¥æ¬å°å ç§åŠäŒçäºäŒã®è³æãèŒããŠããŸããŠãããã«ããã°ã
ãè³çã«ããæ»äº¡äºäŸã® 8å²ã¯è§£ç±å€ãæçšããŠããåã©ããã¡ã
ã§ããããšã瀺ãããŠããŸãã
ããããã40â以äžã®åã©ãã®ç±ã¯äžããŠã¯ãããããã¡ãªãã§ããã
ãŸããšããããç é¢ã§åŠæ¹ããããã®ã¯å šäœãšããŠè¯ããªããšã¯ããããã§ãçµå±ã¯ã
ãç æ°ã«ãªã£ããç é¢ã«è¡ããªããšããéžæãæãæ²»ççã
ãšã¯èšããŸãã
ããã«ãçŸåšäžçäžã«åºããåã©ãã®ãå ç«åªå€±ãã«ãããäºçš®é¡ã ãšãäžçš®é¡ã ãšãã®ããŠã€ã«ã¹ã®å¹²æžæ³åãç¡èŠããäžçã«ããããã§ããããç é¢ã«è¡ããšããè¡çºã¯ããæ°ããªç æ°ãããã£ãŠãããªã¹ã¯ã®ã»ããé«ããªãè¡çºããšããããŸãã
ã¯ã¯ãã³åŸã®å ç«äžå šçå矀ïŒVAIDSïŒã®æžå¿µã¯ã2幎以äžåããå°éå®¶ãã¡ããè¿°ã¹ãããŠããŸããã以äžã«ãããŸãã
ïŒèšäºïŒã³ããã¯ã¯ãã³åŸå€©æ§å
ç«äžå
šçå矀ïŒVAIDSãšãïŒãžã®èŠåã«é¢ããè«æããããã¹ãã¬ãŒããªæé²ãåããå°ããªåã©ããã¡ãžã®æžå¿µãããã«
ãIn Deep 2022幎5æ4æ¥
æ¥æ¬ç£ç§å©Šäººç§åŠäŒãããåŠå©Šãããžã®æ¥çš®ãæšå¥šããå§ããã®ã¯ã2021幎8æ11ã®ããšã§ãããåŠåš æã«ãæ¯ãããæ¥çš®ããŠããå Žåãè質ããç²åã mRNA ããèµ€ã¡ããã«ã¹ãã¬ãŒãã«äŒæããŸãããããã¯çµå±ããèµ€ã¡ããã®äœå ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çç£ãå§ãŸããããšã«ã€ãªãããŸãã
æä¹³ãåãã§ããæ¯ä¹³ãéããŠèµ€ã¡ããã«ãã€ã¬ã¯ãã«äŒæããŸãã
ã¢ã¡ãªã«å»åž«äŒéèª ïŒJAMAïŒã§ããæ¯ä¹³ããã¯ã¯ãã³ mRNA ãæ€åºãããããšããè«æãçºè¡šãããã®ã¯æšå¹Žã®ããšã§ãããã¡ãã®èšäºã§ç¿»èš³ããŠããŸãã
ãã®ããã«èµ€ã¡ããã«äŒããäœå ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãçç£ãããŠãããšâŠâŠãŸãããããããªããšãèµ·ãåŸãã§ãããããã©ããå ç«ããšããããšã«é¢ããŠããã°ã
ã IgG4 æäœãšãããã®ãèªå°ããããããªãã
ãšããããšããããŸãã
ããã¯ã©ããªãã®ããšãããšãããŸãè¯ããªããã®ãïŒææ§ãªè¡šçŸããïŒãªã®ã§ããã以äžã®ããã«ã2åç®æ¥çš®ãã IgG4 ãå¢ãå§ãã3åç®æ¥çš®ããã¯ã壿» çã«å¢å ããŸãã
ãã® IgG4 ã¯ãäžåºŠèªå°ããããšãæ¶ããããšããªãããã®ã§ããèªå°ãããŠã¯ãããªããã®ã§ãã
æè¿ãX ãžã®æ¥æ¬ã®æ¹ã®æçš¿ã§ããã® IgG4 ã«ã€ããŠããšãŠãããããããå³ãæçš¿ãããŠããæ¹ãããã£ããããŸããã
以äžã¯ããã¬ã³ããšã®é¢é£ã§ãã
 IgG4ã¯å ç«ãæå¶ããæäœãšããŠç¥ãããŠãããçã®åå ãšãªããå ·äœçã«ã¯ãIgG4ã¯ä»ã®æäœã®FcéšåãšçµåããŠãå ç«çްèãè£äœã®çµåãé»å®³ããã
ãšæžãããŠãã£ããããŸããã
ãã®æçš¿ã«å¯ŸããŠã®ã³ã¡ã³ãã§ä»¥äžã®ãããªãã®ããããŸããã
IgG4ãIgG1ã®ãŠã£ã«ã¹ãç现èãšãã£ã€ããäœå€ã«æé€ã§ããªããªã墿®ãç¶ãããæ¬æ¥IgG1ããŠã£ã«ã¹ã远ãåºããŠãããã¯ããæ©èœäžèœã§èªå·±å ç«çŸæ£ã§ããã
RoseVivienelove
ããã«ãèªå·±å ç«çŸæ£ããšããèšèãåºãŠããŸãããããã«é¢ããŸããŠãæè¿èŠããã£ã³ã©ã³ãã®ã°ã©ããããä»åŸã«å¯ŸããŠã®åŒ·ãæžå¿µããæ±ããããã®ãšãªã£ãŠããŸããã
以äžã¯ããã£ã³ã©ã³ãã®èªå·±å ç«çŸæ£èšºææ°ã®æšç§»ã§ãã
ãã£ã³ã©ã³ãã®èªå·±å
ç«çŸæ£èšºææ°ã®æšç§»ïŒ2018幎-2023幎ïŒ

Ilkka Rauvola
2023幎ã«ãªã£ãŠãé£ã³æããŠèšºææ°ãå¢ããŠãããããªã®ã§ãã
ãã£ã³ã©ã³ãã¯ãæåã® 2åã®æ¥çš®çã¯é«ãã£ãã§ããïŒ83ïŒ ïŒããã®åŸã®ããŒã¹ã¿ãŒã¯å°ãªããšãé«éœ¢è 以å€ã«ã¯æšå¥šããŠããªãã§ãã®ã§ãã€ãŸãããå€ãã®ãã£ã³ã©ã³ã人ã¯ãæ¥çš®åŸãããã 2幎çµéããŠããããšããããšã«ãªããŸãã
ããã§äžã®ã°ã©ãã®ãããªèªå·±å ç«çŸæ£ã®æšç§»ãšãªã£ãŠããã®ã§ãã
æéã®çµéãšå ±ã«æªåããŠããã
ãŸããå ã»ã©ãèµ€ã¡ãããã«ã€ããŠæžããŸããããã©ãããšãã°ã以äžã®ãããªã°ã©ãããããŸãã乳幌å çªç¶æ»çå矀ãã2021幎ããå¢å ãç¶ããŠãããšãããããªãã®ã§ãã
ç±³ãããå·ã®ã乳幌å
çªç¶æ»çå矀ãã®æšç§»ïŒäººå£10äžäººãããïŒ

James Thorp MD
2021幎ããæ¥æ¿ã«ä¹³å¹Œå çªç¶æ»çå矀ãå¢ããŠããŸãããã 2022幎ã¯ãããã«å¢ããŠãããããšãããããŸãã
ãã®ä¹³å¹Œå çªç¶æ»çå矀ã®ããšã¯ãšããããæ¥æ¬ãå«ããŠãååœã®ããããè¶ éæ»äº¡ã®æ°èªäœã¯ãããèœã¡çããŠããŠããæããããã®ã§ãããå¥ã®é¢ããæžããŸããšã
ãç æ°ã®äººãç°æ§ã«å¢ããŠããå¯èœæ§ãããã
ãšèšããããªæ å¢ã ãšæãããŸãã
ããã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã§èªå°ãããã IgG4 ããšãããã®ã®å ã»ã©ã®èª¬æãããçå±äžãããããã¯äºæž¬ã§ãããããšã§ããããã£ã³ã©ã³ãã®ã°ã©ãã®ããã«ãçŸå®ãããã瀺ããŠããã
èªå·±å ç«çŸæ£ã«ããããããšãããŸãããå€ãã®èªå·±å ç«çŸæ£ã®å Žåãæ©æã®æ»ã«ã€ãªãããããªãã®ã§ã¯ãªãã¯ãã§ãã
ãããããã¯ãç æ°ã§ããããèŠããã
å€ãã®èªå·±å ç«çŸæ£ã¯é·ãç æ°ãšã®ä»ãåãã«ãªãããããã®ã§ãïŒå®æ²»ãããçæ³ããªãããïŒã
ã¬ã³ã«é¢ããŠããæè¿ã¯ãæ¥éã«é²è¡ããã¬ã³ãéåžžã«å€ãèŠããããšããå»çé¢ä¿è ã®æ¹ã ã®æçš¿ãªã©ãèŠãŸãããããããªããã°ãã¬ã³ã«ããŠããããªãé·ãååœãããå Žåãå€ããšæããŸãïŒæã¬ã³å€æ²»çãé¿ããã°ïŒã
ãããããã¯ãç æ°ã ãããèŠããã
ä»åŸããããã人ãã¡ããã®ãããå€ã瀟äŒã®ç¶æ³ã«ãªã£ãŠããããããã¯ããã§ã«ãªã£ãŠãããå¯èœæ§ãé«ãããããŠããã£ã³ã©ã³ãã®ã°ã©ããèŠãŠããŸããšã
ããã®ãããªç æ°ã®æ¹ã ããä»åŸãã©ãã©ãç©ã¿éãªã£ãŠããã
ãšããæããåããŸãã
æ²»ãã«ããç æ°ãå¢å ããå Žåãæ°åãç©ã¿äžãã£ãŠããã ãã®ããšã«ãªãããããšæããŸãã墿žãšããã®ãããŸããªãã
ãã£ã³ã©ã³ãã®ã°ã©ãã¯ãèªå·±å ç«çŸæ£ã®æ°ãäžãã£ãŠããå±é¢ãããŸã ã«èµ·ããŠããªãããšã瀺ããŠããŸãã
ããã«å ããŠãå¿ççãè³ãè¡ç®¡ãç¥çµç³»ã®çŸæ£ãããã®å¢å ãåãŸããšãæããŸããã
以äžã®èšäºã§ã¯ããã®ã¯ã¯ãã³ã«ã¯ãã¬ã³åããããã®ããããã¡ã«ããºã ããçµã¿èŸŒãŸããŠããããšãæžããŸããã
ïŒèšäºïŒãšãããã宿åœçã«ã¬ã³ã¯å¢ããã®ã ãã
ãIn Deep 2023幎9æ26æ¥
ãã£ã³ã©ã³ãã®çµ±èšãèŠãŠããŸããšãæ¥æ¬ã§ããã¬ã³ãšäžŠãã§èªå·±å ç«çŸæ£ãä»åŸãé£èºçã«å¢ããŠããïŒãããã¯ããã§ã«å¢ããŠããïŒã®ã§ã¯ãªãããšäºæ³ãããŸãã
çæ³¢å€§åŠã®ååéºäŒç«åŠç 究宀ã®ããŒãžã«ä»¥äžã®ããã«ãããèªå·±å ç«çŸæ£ã¯ãåºæ¬çã«åŸçºçèŠå ããšã®ããšã§ã倿¥ DNA ãã RNA ãã倧éã«ãäœå ã«å ¥ãã°ãååã«ãã®åŸçºçãªèŠå ãšãªãããæ°ã¯ããŸãã
èªå·±å ç«çŸæ£
å šèº«æ§èªå·±å ç«çŸæ£ã®ä»£è¡šæ Œã§ããè åç ãé¢ç¯ãªãŠããã¯ãç å ãæ¬è³ªçæ²»çæ³ãæããã«ãªã£ãŠããŸããã
æ¬æ¥ãå ç«å¯å®¹ãæç«ããå¶åŸ¡ãããŠããã¯ãã®ãèªå·±æåã«å¯Ÿããå ç«å¿çïŒèªå·±å ç«ïŒã芳å¯ãããã®ãäžã€ã®ç¹åŸŽã§ããããªããããèµ·ããã®ããæããã«ãªã£ãŠããŸããã
âŠãããã®çŸæ£ã¯ãäžã€ã®éºäŒåã®å€ç°ã§çºçã«ãããçŸæ£ã§ã¯ãªãããããã®çŸæ£ã«ãããããããäœè³ª(çŸæ£æåæ§)ãããæã¡ã®æ¹ã«ãäœããã®åŸå€©çå åãå ãã£ãŠçºçã«è³ããšæ³å®ãããŸãã
ãããããçãŸãã€ãæã£ãŠããDNAé åã«ã¯å人差ããããã²ãã DNA倿§æ§ãšåŒã°ããŸããDNAé åã®å人差ã¯ãããªã¢ã³ããããã®äžã§äžè¬éå£ã«ããçšåºŠã®é »åºŠã§ååšãããã®ã¯ãå€åïŒãããïŒããšåŒã°ããŸãã
çŸåšã®èãæ¹ã§ã¯ãã²ãã å šäœã«æ°çŸäžåæååšããããªã¢ã³ãã®ãã¡ã®äžéšããå°ãã ãããçŸæ£ã«å¯Ÿããæåæ§ãé«ãããããäœããããããŸãã
ããšãæè¿ãæ°ã«ãªãè«æããã€ãã£ãŒã«æ²èŒãããŠããã®ã§ãããã©ããã
ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ããã¯ããã¡ãŒãžã«çŽæ¥ææããŠãããã§é·æéãæ€åºãããªããŸãŸãæœãã§ããã
ãšããããã«èªããã®ã§ãããé£ãããŠä»ã²ãšã€ããããŸããããå°ããµããããŠããã ããŸãã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ãHIVæ§ããããã«å£éèŠã
è«æã¯ä»¥äžã«ãããŸãã
èºèãã¯ããã¡ãŒãžã«ããã SARS-CoV-2 ãŠã€ã«ã¹ã®æç¶ã¯ IFN-γ 现èãš NK 现èã«ãã£ãŠå¶åŸ¡ããã
SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells
ãã¯ããã¡ãŒãžãšããã®ã¯ãèªç¶å ç«ã®éèŠãªåœ¹å²ããã€ãã®ã§ãã
ãã¯ããã¡ãŒãžã¯ãçŽåŸ15ïœ20ÎŒmã®æ¯èŒç倧ããªçްèã§ãå šèº«ã®çµç¹ã«åºãååžããŠãããèªç¶å ç«ïŒçãŸãã€ãæã£ãŠããé²åŸ¡æ©æ§ïŒã«ãããŠéèŠãªåœ¹å²ãæ ã£ãŠããŸãã
ãã®çްèã¯ãäœå ã«äŸµå ¥ãã现èãªã©ã®ç°ç©ãé£ã¹ãèœåã«åªããŠãããé£ã¹ã现èãæ¶åã»æ®ºèããããšã§ãçŽ°èææãé²ãã§ããŸãã
ãã®ããã«åããæã€ãã¯ããã¡ãŒãžã«çŽæ¥ææãã¡ãããšã
ãã€ãã£ãŒã®è«æã®ãè°è«ãã®éšåã«ã¯ä»¥äžã®ããã«æžãããŠããŸããè±èªã®èšå·ã¯ãã¹ãŠæ¥æ¬èªã«ããŠããŸãã
è«æãã
æŠæŒ¢åãŸãã¯ãªãã¯ãã³ã® SARS-CoV-2 å€ç°æ ªã䜿çšããŠãææåŸ 6ãæã®æç¹ã§ãææãããã«ã¯25é äž17é ã®æ°ç®¡æ¯èºèæŽæµãããŠã€ã«ã¹ RNAãæ€åºãããææåŸ6ãæã®ãã«ã¯25é äž20é ã®æ°ç®¡æ¯èºèæŽæµãã¯ããã¡ãŒãžãããŠã€ã«ã¹æåãæ€åºãããã
æ°ç®¡æ¯èºèæŽæµãã¯ããã¡ãŒãžã¯ã錻åœé ããã³æ°ç®¡ã®ã¹ã¯ãã§æ€åºã§ããªãå Žåã§ããå°ãªããšã 221dpi ãŸã§è€è£œããããšãã§ããã
âŠã¹ãã€ã¯ã¿ã³ãã¯è³ªç±æ¥ã®ãããã V 3-11ã¯ãäž»èŠçµç¹é©åæ§è€åäœã«çµåããŠãããã¥ã©ã«ãã©ãŒçްèã®è±é¡ç²æŽ»æ§ãé»å®³ããV 3-11ã«ãã£ãŠèªçºãããé»å®³ã®çšåºŠã¯ãŠã€ã«ã¹éããã³æ°ç®¡æ¯èºèæŽæµäžã®ã¹ãã€ã¯ + ãã¯ããã¡ãŒãžã®ååšãšææã«çžé¢ãããæŠæŒ¢åããã³ãªãã¯ãã³ãææãããã«ãã¯ã€ã¶ã«ã®ããã¥ã©ã«ãã©ãŒçްèã¯ãV 3-11ã®é»å®³å¹æã«å¯ŸããŠããé«åºŠãªèæ§ãæã£ãŠããã
ãããã錻åœé ãæ°ç®¡ã§ã®ã³ããæ€æ»ã§ãé°æ§ãã瀺ãããåŸãã6ãµæéãã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã
ãè€è£œã§ããç¶æ ã§ãã¯ããã¡ãŒãžã«æœãã§ããã
ãšãããããªããšãæžãããŠããããã«æãããã®ã§ããâŠã
ããã§ã¯ãèªç¶ã®ã³ãããŠã€ã«ã¹ã®ææç ç©¶ã§ãããææã®äž»äœã¯ã¹ãã€ã¯ã¿ã³ãã¯è³ªã§ãã®ã§ãã¯ã¯ãã³ãåæ§ã§ãïŒããããã¯ã¯ãã³ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯åŒ·ãïŒã
ããã¥ã©ã«ãã©ãŒçްèã®æŽ»æ§ãé»å®³ããããããããã§ãã
ã HIV è²ãããã«åŒ·ããªã£ãŠãããããªæ°ãããâŠã
ãšæããããåŸãŸããã
æ°åã³ããã®ã HIV æ§ãã¯ãã¯ã¯ãã³ä»¥åã®ãä»ãã 3幎以äžåã«ã¯ãããã¯ãããŠããŠãããã§ãåä»ãªãŠã€ã«ã¹ã ãªãããšæã£ããã®ã§ããã
ïŒèšäºïŒïŒ»è¡æïŒœ æ°åã³ãããŠã€ã«ã¹ã¯ã人éã®å
ç«æ©èœã®äžå¿ã§ãã现èãæ»æãããå
ç«ç³»ãå®å
šã«ç Žå£ãããHIVãšåãç¹åŸŽãæã£ãŠãããããšãç±³äžã®ç ç©¶è
ã«ãã確èªããã
In Deep 2020幎4æ13æ¥
ãã®é ã¯ãã¯ã¯ãã³ãç»å Žãããšãããããªããšã¯å€¢ã«ãæã£ãŠããªãã£ãææã§ãããåœæããã
ãã³ããã£ãŠãæ°å¹ŽåŸãããæãåé¡ã«ãªãã®ã§ã¯ã
ãšã¯æŒ ç¶ãšã¯æã£ãŠããŸããã
å ã»ã©ã®ãã€ãã£ãŒã®è«æãèªãã§ãããšãã°ã
ãã¯ã¯ãã³ã¹ãã€ã¯ãããã¯ããã¡ãŒãžã«æä¹ çã«æœã¿ç¶ããã®ã ãšããã°ïŒã
ãšãããããªããšãèããŸãã
ãããŠãHIV åæ§ããçºçããå Žåã«ã¯ãæ°å¹Žãªã©ããããŠãå ç«äžå šç¶æ ãèããæªåããŠããã®ã§ã¯ïŒããšãããããªããšãããµãšæããŸãã
å®éã«ã¯ããã®è«æã¯ç§ã«ã¯ããŸãã«ãé£è§£ã§ãè§£éãééã£ãŠããå¯èœæ§ãé«ãã§ãããã詳ããæ¹ã«èªãã§ããã ããã°ãšæããŸããèªç¶ææã®èгç¹ã§ã¯ãªããäžçã§æ°ååäººãæ¥çš®ãããã¯ã¯ãã³ã®èгç¹ãã§èªãŸããŠããã ããã°ããã®è¿«åãããããã«ãªãã®ã§ã¯ãªãããšãæããŸãã
倧éã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãé·æéã«ããã£ãŠçç£ãç¶ããã¯ã¯ãã³ã®åœ±é¿ããæ¬æ Œçã«ãªãã®ã¯ãæ°å¹ŽåŸããïŒããšãæŒ ç¶ã§ã¯ãã£ãŠãæããŸãã
ããã«ããŠããã¹ãã€ã¯ã¿ã³ãã¯è³ªãšããã®ã¯ãã©ã®é¢ããèŠãŠãããã®ãããååšãšããèšãããããªãã§ãã
>> In Deep ã¡ã«ãã¬ã®ãæ¡å
In Deepã§ã¯ã¡ã«ãã¬ãçºè¡ããŠããŸããããã°ã§ã¯ããŸããµãã«ããããšãªã©ãå«ããŠãæ¯é±éææ¥ã«é
ä¿¡ãããŠãããã ããŠããŸããã詊ãæã¯ç¡æã§ããã®æéäžã«ãããã«ãªãããšãã§ããŸãã®ã§ãã詊ãäžããã°å¹žãã§ãããã¡ããã¯ãªãã¯ãããã以äžãããç»é²ã§ããŸãã
▶ ãç»é²ãžé²ã


